2011
DOI: 10.1016/j.apradiso.2011.03.022
|View full text |Cite
|
Sign up to set email alerts
|

Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
40
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 53 publications
(40 citation statements)
references
References 11 publications
0
40
0
Order By: Relevance
“…Use of these agents for BNCT of GBM, melanoma, and head and neck cancers has met with limited success; treatments are largely palliative or last-line and are therefore only marginally more effective than conventional external-beam radiation therapy in increasing survival times (10)(11)(12)(13)(14)(15). With BNCT research having been so limited in scope, many agents that might have been highly effective against other more treatable types of cancer were never evaluated beyond preliminary studies.…”
mentioning
confidence: 99%
“…Use of these agents for BNCT of GBM, melanoma, and head and neck cancers has met with limited success; treatments are largely palliative or last-line and are therefore only marginally more effective than conventional external-beam radiation therapy in increasing survival times (10)(11)(12)(13)(14)(15). With BNCT research having been so limited in scope, many agents that might have been highly effective against other more treatable types of cancer were never evaluated beyond preliminary studies.…”
mentioning
confidence: 99%
“…Clinical trials of BNCT for the treatment of glioblastoma multiforme and/or melanoma and, more recently, head and neck tumors and liver metastases, using boronophenylalanine (BPA) or sodium mercaptoundecahydrododecaborane as the 10 B carriers, have been performed or are under way in Argentina, Europe, Japan, Taiwan, and the United States (4)(5)(6)(7)(8). These treatments have been marginally more effective than external-beam radiation therapy (9)(10)(11).…”
mentioning
confidence: 99%
“…The requirements for successful BNCT are preferential accumulation and retention of a nontoxic 10 B carrier in a tumor, a sufficiently high absolute concentration of 10 B in tumor tissue (at least 20 ppm) for a sufficient number of 10 B(n,α) 7 Li reactions to occur, and targeting of all tumor cell populations (12)(13)(14). Furthermore, the microlocalization of 10 B also determines the therapeutic outcome of BNCT (15).…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…The accumulated boron absorbs the neutrons and releases high energy particles, destroying the tumor cells 118 . BNCT has achieved some success in head-and-neck cancers 119 , as well as GBM 120,121 , but it is believed that FUS-mediated BBBD may improve BNCT efficacy by increasing the concentration of boron in the tumor tissue. Several rodent studies 104,122,123 have demonstrated that FUS significantly increases the concentration of BPAf, a boron containing drug, in tumor tissue, as well as homogenizing distribution 104 .…”
Section: Drug Deliverymentioning
confidence: 99%